Stockscreener 앱 받기
1.78
2.20%
-0.04
시간 외 거래:
1.82
0.04
+2.25%
전일 마감가:
$1.82
열려 있는:
$1.82
하루 거래량:
167.75K
Relative Volume:
0.51
시가총액:
$1.06M
수익:
-
순이익/손실:
$-8.26M
주가수익비율:
-0.0332
EPS:
-53.609
순현금흐름:
$-12.17M
1주 성능:
+21.92%
1개월 성능:
-59.23%
6개월 성능:
-84.52%
1년 성능:
-98.13%
1일 변동 폭
$1.69
$1.93
1주일 범위
$1.42
$2.11
52주 변동 폭
$1.10
$106.04
Gri Bio Inc Stock (GRI) Company Profile
명칭
Gri Bio Inc
전화
(619) 400-1171
주소
2223 AVENIDA DE LA PLAYA, LA JOLLA
GRI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
1.78 | 1.06M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-09 | 개시 | H.C. Wainwright | Buy |
Gri Bio Inc 주식(GRI)의 최신 뉴스
GRI Bio Inc (GRI) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
FY2025 Earnings Forecast for GRI Bio Issued By HC Wainwright - Defense World
GRI Bio appoints Withum as new accounting firm By Investing.com - Investing.com Canada
GRI Bio Announces Abstract Selected for Poster Discussion - GlobeNewswire
Major Scientific Breakthrough: GRI Bio's Novel Pulmonary Fibrosis Treatment Shows Promise - Stock Titan
GRI Bio appoints Withum as new accounting firm - Investing.com Australia
GRI Bio (NASDAQ:GRI) Given Buy Rating at HC Wainwright - Defense World
H.C. Wainwright maintains Buy on GRI Bio stock, $10 target - Investing.com Australia
H.C. Wainwright maintains Buy on GRI Bio stock, $10 target By Investing.com - Investing.com South Africa
GRI stock touches 52-week low at $1.2 amid market fluctuations - Investing.com
GRI Bio regains compliance with Nasdaq’s minimum bid price rule - MSN
GRI Bio Announces Closing of $5.0 Million Public Offering - The Manila Times
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data - MSN
Gri Bio Announces Closing Of $5.0 Million Public Offering - MarketScreener
GRI Bio Raises $5M, Eyes $18.3M Total Potential for Breakthrough Autoimmune Treatment - Stock Titan
GRI Stock Down On Public Offering Despite Encouraging IPF Study Data - Barchart.com
GRI Bio Shares Rebound In After-Hours Trading - Stocks Telegraph
GRI Bio (GRI) Reports Positive Interim Safety Results for IPF Tr - GuruFocus
Street can a-GRI on phase IIb safety win in IPF with tazarotene - BioWorld MedTech
GRI Bio Announces $5 Million Public Offering Amid Market Decline - Nasdaq
GRI Bio Prices up to $13 Million Equity Offering - marketscreener.com
GRI Bio announces $5 million public offering - Investing.com
GRI Bio announces $5 million public offering By Investing.com - Investing.com India
GRI Bio Announces Pricing of $5.0 Million Public Offering - GlobeNewswire
GRI Bio Secures $5M Funding Deal: Warrants Could Add $13.3M More - Stock Titan
Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?GRI Bio (NASDAQ:GRI) - Benzinga
GRI Bio’s IPF drug shows promise in early trial By Investing.com - Investing.com South Africa
GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF - The Manila Times
GRI Bio reports interim 2-week safety results from Phase 2a study of GRI-0621 - TipRanks
GRI Bio’s IPF drug shows promise in early trial - Investing.com
Gri Bio IncIDMC Recommends Continuation Of Study With No Safety Concerns - MarketScreener
GRI Bio Reports Encouraging Interim 2-Week Safety Results - GlobeNewswire
Clinical Trial Breakthrough: GRI-0621 Clears Key Safety Milestone for IPF Treatment - Stock Titan
GRI Bio secures global patents for NKT cell modulators By Investing.com - Investing.com South Africa
GRI Bio secures global patents for NKT cell modulators - Investing.com
GRI Bio announces the granting of two global patents for Europe, Japan - TipRanks
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan - GlobeNewswire
Global Patent Victory: GRI Bio's Breakthrough NKT Cell Treatment for Autoimmune Disease Gets Dual Approval - Stock Titan
Vallon Pharmaceuticals stock plunges to 52-week low of $4.95 By Investing.com - Investing.com South Africa
Vallon Pharmaceuticals stock plunges to 52-week low of $4.95 - Investing.com India
GRI Bio (GRI) to Release Quarterly Earnings on Thursday - Defense World
GRI Bio Participates in a Virtual Investor CEO Connect Segment - The Manila Times
GRI Bio's Breakthrough IPF Drug Shows Promise, Key Data Coming Next Quarter - StockTitan
Gri Bio Inc (GRI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.19%
자본화:
|
볼륨(24시간):